Elite Pharmaceuticals Inc. /NV/ (ELTP) intrinsic value & 10-year financials
Elite Pharmaceuticals Inc. /NV/ (ELTP) has a Graham intrinsic value of $1.00 per share. At $0.25 on Oct 17, 2026, the stock trades 75% below that value. Over the last 10 fiscal years revenue grew 35.5% a year to $148.9M, with an average return on invested capital of 29.4%.
- Graham intrinsic value
- $1.00
- Share price (Oct 17, 2026)
- $0.25
- Price vs Graham value
- 75% below
- Market cap
- $284.6M
- Revenue (FY2026)
- $148.9M
- Revenue growth (10-yr CAGR)
- 35.5%
- ROIC (10-yr avg)
- 29.4%
- Free cash flow (FY2026)
- $22.8M
ELTP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $148.9M | $44.9M | $0.03 | $22.8M | 33.0% | 66.9% |
| FY2025 | $84.0M | -$4.3M | $0.00 | $5.8M | 23.3% | 39.6% |
| FY2024 | $56.6M | $20.1M | $0.02 | -$4.1M | 19.1% | 20.0% |
| FY2023 | $34.2M | $3.6M | $0.00 | -$2.4M | 10.8% | — |
| FY2022 | $32.3M | $8.9M | $0.01 | $6.0M | 15.7% | 30.5% |
| FY2021 | $25.4M | $5.1M | $0.01 | $2.9M | 8.3% | 39.5% |
| FY2020 | $18.0M | -$2.2M | $0.00 | -$1.8M | -12.7% | -19.9% |
| FY2019 | $7.6M | -$9.3M | -$0.01 | -$6.8M | -121.0% | — |
| FY2018 | $7.5M | -$3.7M | -$0.01 | -$5.0M | -121.4% | — |
| FY2017 | $9.6M | $3.8M | -$0.01 | -$9.0M | -76.3% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ELITE PHARMACEUTICALS INC /NV/ is a consistent compounder, expanding top-line revenue at 35.5% annually over the past decade.
ELITE PHARMACEUTICALS INC /NV/ has earned high returns on invested capital, averaging 29.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
ELITE PHARMACEUTICALS INC /NV/ has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ELITE PHARMACEUTICALS INC /NV/ is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.00 per share.